The company's product candidate portfolio includes treatments for rheumatoid arthritis, Crohn's disease, ulcerative colitis, cystic fibrosis, idiopathic pulmonary disease, osteoarthritis, and atopic dermatitis. Galapagos is fully integrated and committed to improving patients' lives worldwide by targeting diseases with high unmet needs. They cover multiple drug modalities, including small molecules and cell therapies, and have programs in immunology, oncology, and other indications. Their first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.